Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Serum chemerin and diabetic retinopathy in type 2 diabetic patients

The Egyptian Journal of Internal Medicine volume 29, pages 117–121 (2017)Cite this article

Abstract

Background

Diabetic retinopathy (DR) is one of the microvascular complications of type 2 diabetes mellitus (T2DM). There is a need to find a reliable screening biomarker to help in the early diagnosis of this complication.

The aim of the work was to study the relation between serum chemerin and DR in T2DM patients.

Patients and methods

This study was conducted on 80 T2DM patients in addition to 20 healthy individuals who served as a control group. The participants were grouped into four groups: the T2DM group, the nonproliferative diabetic retinopathy (NPDR) group, the proliferative diabetic retinopathy (PDR) group, and the control group. Laboratory investigations were performed to all participants, which included glycosylated hemoglobin (HbA1c), serum creatinine, lipid profile, urine albumin/creatinine ratio, C-reactive protein (CRP), and serum chemerin. Fundus examination was carried out to all participants by an expert ophthalmologist.

Results

Serum chemerin was significantly higher in the PDR group compared with the other groups, in the NPDR group compared with the T2DM group and controls, and in the T2DM group compared with controls. There was a positive significant correlation between serum chemerin and BMI, HbA1c, diabetes mellitus duration, serum total cholesterol, triglycerides, low density lipoprotein, and CRP and a negative significant correlation between serum chemerin and high density lipoprotein in diabetic patients.

Conclusion

From this study, we can conclude that serum chemerin is significantly higher in patients with DR compared with diabetic patients without retinopathy and in PDR patients compared with NPDR patients. There is a positive correlation between serum chemerin and CRP, BMI, and lipid profile.

References

  1. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34:2–11.

    Article  CAS  Google Scholar 

  2. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011; 12:3117–3132.

    Article  Google Scholar 

  3. Pusparajah P, Lee L, Abdul Kadir K. Molecular markers of diabetic retinopathy: potential screening tool of the future? Front Physiol 2016; 7:200.

    Article  Google Scholar 

  4. Boehm B, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor [PEDF] in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003; 46:394–400.

    Article  CAS  Google Scholar 

  5. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282:28175–28188.

    Article  CAS  Google Scholar 

  6. Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor [ChemR23] in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010; 391:1762–1768.

    Article  CAS  Google Scholar 

  7. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011; 28:1194–1200.

    Article  CAS  Google Scholar 

  8. Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, et al. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab 2012; 58:539–544.

    CAS  PubMed  Google Scholar 

  9. Told R, Baratsits M, Garhöfer G, Schmetterer L. Early treatment diabetic retinopathy study [ETDRS] visual acuity. Ophthalmologe 2013; 110:960–965.

    Article  CAS  Google Scholar 

  10. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009; 94:3085–3088.

    Article  CAS  Google Scholar 

  11. Takahashi M, Inomata S, Okimura Y, Iguchi G, Fukuoka H, Miyake K, et al. Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism. Endocr J 2013; 60:37–44.

    Article  CAS  Google Scholar 

  12. Hu W, Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabet Res Clin Pract 2011; 91:159–163.

    Article  CAS  Google Scholar 

  13. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M et al. Chemerin—a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007; 362:1013–1018.

    Article  CAS  Google Scholar 

  14. Van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002; 25:1320–1325.

    Article  Google Scholar 

  15. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FR. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003; 110:2126–2133.

    Article  Google Scholar 

  16. Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med 2010; 58:883–886.

    Article  CAS  Google Scholar 

  17. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161:339–344.

    Article  CAS  Google Scholar 

  18. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010; 72:342–348.

    Article  CAS  Google Scholar 

  19. Ying Z, Qian W, Kaiping H. Correlation between type-2 diabetic patient chemerin level changes and lower extremity venous disease. J Shandong Uni Med 2011; 49:9–12.

    Google Scholar 

  20. ChunlianC, Yufang Y, Zhicheng W. Study of the correlation between serum chemerin and C-reactive protein levels of type-2 diabetic patients and insulin-resistance and macroangiopathy J Chinese General Practice. 2013; 16:2438–2440.

    Google Scholar 

  21. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010; 185:3728–3739.

    Article  CAS  Google Scholar 

  22. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148:4687–4694.

    Article  CAS  Google Scholar 

  23. Yamamoto T, Qureshi AR, Anderstam B, Heimburger O, Barany P, Lindholm B, et al. Clinical importance of an elevated circulating chemerin level in incident dialysis patients. Nephrol Dial Transplant 2010; 25:4017–4023.

    Article  CAS  Google Scholar 

  24. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011; 34:307–310.

    Article  CAS  Google Scholar 

  25. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002; 86:363–365.

    Article  CAS  Google Scholar 

  26. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res 2006; 82:798–806.

    Article  CAS  Google Scholar 

  27. Abu EA, Struyf S, Kangave D, Geboes K, van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 2006; 17:155–165.

    Google Scholar 

  28. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin-8, monocyte chemo-attractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005; 22:719–722.

    Article  CAS  Google Scholar 

  29. Du J, Li R, Xu L, Ma R, Liu J, Cheng J, Zhang Z, Sun H. Serum chemerin levels in diabetic retinopathy of type 2 diabetic patients. Curr Eye Res 2016; 41:114–120.

    Article  CAS  Google Scholar 

  30. Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D, Konstantopoulos N, et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab 2010; 95:2476–2485.

    Article  CAS  Google Scholar 

  31. Kasai A, Ishimaru Y, Kinjo T, Satooka T, Matsumoto N, Yoshioka Y, et al. Apelin is a crucial factor for hypoxiainduced retinal angiogenesis. Arterioscler Thromb Vasc Biol 2010; 30:2182–2187.

    Article  CAS  Google Scholar 

  32. Rosen LB, Ginty DD, Weber MJ, Greenberg ME. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 1994; 12:1207–1221.

    Article  CAS  Google Scholar 

  33. Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992; 258:478–480.

    Article  CAS  Google Scholar 

  34. Aoka Y, Johnson FL, Penta K, Hirata Ki K, Hidai C, Schatzman R, et al. The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Microvasc Res 2002; 64:148–161.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assistant Professor in Internal Medicine Department, Faculty of Medicine, Menoufia University, 5 Fatma Elyosef Street, Sporting, Alexandria, Egypt

    Alaaeldin Abdelsalam Dawood (MD)

  2. Lecturer in Ophthalmology Department, Faculty of Medicine, Menoufia University, Alexandria, Egypt

    Osama Abdalah Elmorsy

  3. Assistant Prof Clinical Pathology, Pharmacology and Toxicology Department, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt

    Hala Mourad Demerdash

Authors
  1. Alaaeldin Abdelsalam Dawood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osama Abdalah Elmorsy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hala Mourad Demerdash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alaaeldin Abdelsalam Dawood.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dawood, A.A., Elmorsy, O.A. & Demerdash, H.M. Serum chemerin and diabetic retinopathy in type 2 diabetic patients. Egypt J Intern Med 29, 117–121 (2017). https://doi.org/10.4103/ejim.ejim_30_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_30_17

Keywords